James Roach - Pulmatrix Chief Medical Officer
| PULM Stock | USD 2.02 0.03 1.51% |
Executive
Dr. James M. Roach, MD. FACP, FCCP., is no longer Chief Medical Officer of the Company, effective March 8, 2019. Most recently, Dr. Roach was Chief Medical Officer at Veristat. Prior to joining Veristat, he served as Senior Vice President, Development and Chief Medical Officer of Momenta Pharmaceuticals, Senior Vice President, Medical Affairs at Sepracor Pharmaceuticals, and Head of Medical Affairs at Millennium Pharmaceuticals
| Professional Marks | Ph.D |
| Address | 99 Hayden Avenue, Lexington, MA, United States, 02421 |
| Phone | 781 357 2333 |
| Web | https://www.pulmatrix.com |
Pulmatrix Management Efficiency
The company has return on total asset (ROA) of (0.246) % which means that it has lost $0.246 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5752) %, meaning that it created substantial loss on money invested by shareholders. Pulmatrix's management efficiency ratios could be used to measure how well Pulmatrix manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.52. At this time, Pulmatrix's Total Current Assets are very stable compared to the past year. As of the 24th of April 2024, Net Tangible Assets is likely to grow to about 37.6 M, while Non Current Assets Total are likely to drop about 8.2 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Valerie Mosley | Evotec SE ADR | 57 | |
| Lisa Wilson | Eagle Pharmaceuticals | N/A | |
| Declan OConnor | Alkermes Plc | N/A | |
| Scott Eston | Evotec SE ADR | 60 | |
| James Kirchner | Evotec SE ADR | 50 | |
| Umesh Mahajan | Silver Spike Investment | 53 | |
| MBA MPA | Evotec SE ADR | 56 | |
| Peter Norman | Alkermes Plc | N/A | |
| Craig MD | Alkermes Plc | 56 | |
| Daniel Cataldo | Evotec SE ADR | N/A | |
| Roxanne Jenkins | Silver Spike Investment | 38 | |
| Paula Hawkings | Evotec SE ADR | N/A | |
| Rachel Nottingham | Evotec SE ADR | N/A | |
| Helen Peters | Evotec SE ADR | 69 | |
| Ronald Pearlman | Evotec SE ADR | 76 | |
| Volker Braun | Evotec SE ADR | N/A | |
| Monika Conradt | Evotec SE ADR | N/A | |
| Reed McClung | Eagle Pharmaceuticals | N/A | |
| Beverley Gordon | Evotec SE ADR | N/A | |
| Iain Brown | Alkermes Plc | 55 | |
| Kirsten Long | Evotec SE ADR | N/A | |
Management Performance
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.25 |
Pulmatrix Leadership Team
Elected by the shareholders, the Pulmatrix's board of directors comprises two types of representatives: Pulmatrix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pulmatrix. The board's role is to monitor Pulmatrix's management team and ensure that shareholders' interests are well served. Pulmatrix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pulmatrix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA CMA, Interim Officer | ||
| Terrance McGuire, Director | ||
| Matthew Sherman, Director | ||
| David Hava, Chief Scientific Officer | ||
| Alexander Klibanov, Founder | ||
| Akihisa Akao, Director | ||
| James Roach, Chief Medical Officer | ||
| Michael Higgins, Director | ||
| Steven Gillis, Director | ||
| Jean Sung, Vice President - Pharmaceutical Development | ||
| William Duke, CFO, Principal Financial Officer & Principal Accounting Officer | ||
| Robert Clarke, CEO and President and Director | ||
| Scott Rocklage, Director | ||
| Kurt Graves, Director | ||
| Richard Conley, Independent Director | ||
| Mark Iwicki, Chairman of the Board | ||
| Amit Munshi, Director | ||
| Gregory French, Independent Director | ||
| Margaret MD, Chief Officer | ||
| Ted Raad, CEO, Director | ||
| David JD, Advisor | ||
| Aidan Curran, VP Affairs | ||
| Teofilo MBA, CEO President | ||
| Teofilo Raad, CEO, Director |
Pulmatrix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pulmatrix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.25 | ||||
| Profit Margin | (1.93) % | ||||
| Operating Margin | (1.01) % | ||||
| Current Valuation | (3.06 M) | ||||
| Shares Outstanding | 3.65 M | ||||
| Shares Owned By Institutions | 8.59 % | ||||
| Number Of Shares Shorted | 2.66 K | ||||
| Price To Earning | (1.30) X | ||||
| Price To Book | 0.44 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pulmatrix using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Complementary Tools for Pulmatrix Stock analysis
When running Pulmatrix's price analysis, check to measure Pulmatrix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pulmatrix is operating at the current time. Most of Pulmatrix's value examination focuses on studying past and present price action to predict the probability of Pulmatrix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pulmatrix's price. Additionally, you may evaluate how the addition of Pulmatrix to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Pulmatrix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.87) | Revenue Per Share 1.998 | Quarterly Revenue Growth 0.289 | Return On Assets (0.25) | Return On Equity (0.58) |
The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.